Menu

TORAYMYXIN®

Toraymyxin® Polymyxin B hemoperfusion therapy – (Toray Industries Ltd., Japan) is the state-of-the-art therapy for the treatment of patients with endotoxic septic shock who are unresponsive to conventional treatment. More than 150,000 patients have been treated with this innovative therapy and more than 250 peer-reviewed articles have been published demonstrating the safety and effectiveness of Polymyxin B hemoperfusion therapy.

Polymyxin B hemoperfusion therapy takes advantage of the strong endotoxin neutralizing capability of Polymyxin B intelligently immobilized to polystyrene fibers. The innovation by TORAY proposing Polymyxin B (polycationic antibiotic) therapy by means of extracorporeal hemoperfusion has provided the most effective therapy for the neutralization of endotoxin, a pathogen and potent killer, when present in the blood stream.

Toraymyxin® is the reference for the treatment of patients with endotoxic septic shock who are unresponsive to conventional therapies. With an endotoxin removal capacity of 640,000 endotoxin units, the high affinity binding may remove up to 90% of circulating endotoxin after two hemoperfusion treatments. Since its introduction, more than 150,000 patients have been treated with polymyxin B hemoperfusion (PMX-HP), with a low incidence of reported adverse events (<1%) and high tolerability. More than 250 peer-reviewed articles have been published and numerous clinical studies have demonstrated that PMX-HP therapy has a positive effect on hemodynamics, organ function and survival in patients with septic shock.

Although PMX-HP therapy was designed to adsorb endotoxin, other mechanisms of immunomodulation have been demonstrated. Some of these mechanisms are caused by elimination of endotoxin, while others result from the direct adsorption of inflammatory mediators, such as activated monocytes and inactivation of circulating renal apoptotic factors. PMX-HP is currently the only therapy available to effectively neutralize both endotoxin and inflammatory mediators in patients with septic shock.

 

Polymyxin B hemoperfusion therapy (Toraymyxin®):

  • Adsorption of circulating endotoxin (Device Adsorption Capacity: 640,000 EU)
  • Adsorption of activated monocytes
  • Rescue of the immune balance
  • Fast recovery of hemodynamics and organ dysfunction
  • Over than 250 peer-reviewed articles published
  • More than 150,000 patients treated with PMX-HP
  • A dedicated diagnostic test available (EAA™)